Lucid Diligence Brief: Galecto acquires Damora Therapeutics
Lucid Diligence Brief: Galecto acquires Damora Therapeutics Professional…
Lucid Diligence Brief: Electra Therapeutics $183M Series C
Lucid Diligence Brief: Electra Therapeutics $183M Series C Professional…
Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025)
This week’s hematology update highlights groundbreaking CAR-T and gene therapy…
Women's Health Weekly News - August 20th 2025
Women’s Health Breakthroughs: Migraine, Fibromyalgia, Postpartum Depression and…
Rare Diseases Weekly News - August 14th 2025
🧬 This Week in Rare Diseases: FDA Approvals, Global Partnerships, Breakthrough…
Rare Diseases Weekly News - July 31st 2025
🧬 This Week in Rare Diseases: FDA Leadership, Gene Therapy Safety, New Drug…
EHA 2025 Preview: Key Hematology Highlights to Watch
EHA at a glance Join LucidQuest for a concise EHA 2025 preview, focusing on…
Cell and Gene Therapy Weekly News - May 29th 2025
This Week in Gene & Cell Therapy: Clinical Trial Expansions, Rare Disease…
How a pharma in the multiple myeloma space gained access to leading KOLs insights and used them in its asset development process.
The Challenge: Understanding how KOLs define the treatment evolution and the…
How we helped two pharma companies assess their own and their competitors' social media during ESMO 2023 and ASCO 2023.
The Challenge: How to maximize the benefits of social media monitoring during…
How our benchmarking analysis contributed to a Hemato-Oncology company's sales and pricing strategy for specific agents.
The Challenge: Competitive benchmarking, including sales force and market…
How a hematology brand utilized competitor sales force research to defend itself against a competitor entrant in Spain.
The Challenge: How to react to a new entrant threat A hematology brand team of…